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Background: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent
need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a
representative sample of Mycobacterium tuberculosis (MTB) isolates. Basing on findings of the molecular epidemiological
study in Kampala, we hypothesized that the predominant MTB strain lineage in Uganda is negatively associated with
anti-TB drug resistance and we set out to test this hypothesis.
Methods: We extracted DNA from mycobacterial isolates collected from smear-positive TB patients in the national TB
drug resistance survey and carried out IS6110-PCR. To identify MTB lineages/sub lineages RT-PCR SNP was performed
using specific primers and hybridization probes and the ‘melting curve’ analysis was done to distinguish the Uganda II
family from other MTB families. The primary outcome was the distribution of the Uganda II family and its associations
with anti-TB drug resistance and HIV infection.
Results: Out of the 1537 patients enrolled, MTB isolates for 1001 patients were available for SNP analysis for
identification of Uganda II family, of which 973 (97%) had conclusive RT-PCR results. Of these 422 (43.4%) were of the
Uganda II family, mostly distributed in the south west zone (55.0%; OR = 4.6 for comparison with other zones; 95% CI
2.83-7.57; p < 0.001) but occurred in each of the other seven geographic zones at varying levels. Compared to the
Uganda II family, other genotypes as a group were more likely to be resistant to any anti-TB drug (ORadj =2.9; 95% CI
1.63-5.06; p = 0.001) or MDR (ORadj 4.9; 95% CI, 1.15-20.60; p = 0.032), even after adjusting for geographic zone, patient
category, sex, residence and HIV status. It was commonest in the 25–34 year age group 159/330 (48.2%). No association
was observed between Uganda II family and HIV infection.
Conclusion: The Uganda II family is a major cause of morbidity due to TB in all NTLP zones in Uganda. It is less likely to
be resistant to anti-TB drugs than other MTB strain lineages.Background
Tuberculosis (TB) remains one of the major causes of
morbidity and mortality, estimated to affect a third of
the population worldwide. Through the past two to
three decades TB incidence and mortality have markedly
increased as a result of HIV [1], and an estimated half
million multidrug resistant (MDR) TB cases exist across* Correspondence: mlj10@case.edu
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unless otherwise stated.the world. The association between MDR-TB and HIV
infection in sub-Saharan Africa (SSA) remains a controversial
subject with no association documented in most settings
[2-5], although some studies continue to report an
association between these two disease epidemics at
individual level [6-9]. The increasing global burden
of MDR-TB underscores the urgent need for pathogen
and host data on factors involved in generation and spread
of drug resistant strains, so as to facilitate focussed
interventions by the national programs for its control [10],
especially in low resource and high burden TB, HIV and
TB/HIV co-infection settings such as SSA.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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countries worldwide with an estimated 293 per 100,000
incident cases of all TB forms in 2010 [11]. It has a high
HIV prevalence, currently estimated at 7.3% among the
15–49 years age group in the general population (AIS
2011), with a TB/HIV co-infection rate of 54% in the
2010 TB cohort [11]. Results from the national drug re-
sistance survey show the prevalence of MDR-TB to be
low; 2.3% among sputum smear-positive new and previ-
ously treated TB patients combined [5].
Molecular epidemiological studies are useful for under-
standing key aspects of TB control including transmission,
potential to cause disease outbreaks, and resistance to
anti-TB drugs [8,12,13], among others. Molecular tech-
niques commonly used in these studies [14,15] include
spacer oligonucleotide typing (spoligotyping), region of
difference (RD) analysis, mycobacteria insertion repetitive
units (MIRU) analysis, insertion sequence 6110 (IS6110)
restriction fragment length polymorphism (RFLP) [13,14],
single nucleotide polymorphisms (SNP) and whole gen-
ome sequencing now the gold standard. Among these,
SNPs represent reliable markers for lineage classification
of Mycobacterium tuberculosis complex [16,17].
The Uganda II genotype is a sub lineage of the MTB
lineage 4, the Euro- American lineage which is defined by
RD 724 deletion [18]. By spoligotyping, it is defined by de-
letion of spacer 33–36 and spacer 40 [19]. Using the highly
sensitive and specific SNP technique, the Uganda family is
further subdivided into the Uganda I and Uganda II sub-
types which contribute 15% and 85% respectively to this
family in Uganda, although these studies were limited with
respect to geographical coverage [20,21]. Earlier studies
have identified the T2 family in general as an important
MTB genotype in specific localities in Uganda [19,20] and
shown a negative association with drug resistance in a lim-
ited geographic setting [22]. This finding is potentially
relevant for understanding the role of genotype diversity
in the epidemiology of TB drug resistance in Uganda and
elsewhere in East Africa, but calls for confirmation in a
geographically more diverse dataset, among others to es-
tablish whether unrelated regional differences in genotype
distribution could confound this association. Our hypoth-
esis in this study therefore was that the Uganda II MTB
subtype is the major cause of morbidity due to tubercu-
losis in Uganda and is negatively associated with anti-TB
drug resistance, and we aimed at testing this hypothesis in
a larger and geographically representative data set.
Methods
Sampling and sample size estimation
The study included new and previously treated sputum
smear-positive TB patients enrolled in a national anti-TB
drug resistance survey from all the NTLP zones excluding
the Central Zone (see Figure 1). This was a cross-sectionalsurvey that included 44 TB diagnostic and treatment units
across the nine TB control zones (DTUs) in the country
(Figure 1). A cluster sampling method was used in which 30
clusters (primary sampling units) were selected randomly
with probability proportional to the number of smear-
positive TB patients registered in 2007. Within each cluster
a fixed number of consecutively diagnosed smear-positive
patients were enrolled so that all included patients had iden-
tical sampling probabilities. Each cluster was required to
enrol 50 new sputum smear-positive TB patients (for a tar-
get sample size of 1500 patients) within one year, plus all
the previously treated patients diagnosed during this period.
Laboratory methods
Sputum collection
Each eligible patient who consented provided two spu-
tum samples, an early morning and a spot sample, inde-
pendent of the routine samples used for diagnostic
purposes to minimize chances of contamination. Sam-
ples were refrigerated at 4°C and then transported to the
National TB Reference Laboratory (NTRL) for process-
ing via a local courier system.
Sputum culture and drug susceptibility testing
At the NTRL, samples were decontaminated using the
1.5% NaOH NALC method and processed. The sample
was inoculated on two slopes of Löwenstein-Jensen (L-J)
medium, incubated at a temperature of 37°C and moni-
tored weekly for growth up to 8 weeks. A culture was only
reported negative if no growth was shown after 8 weeks.
For the positive cultures identification of MTB was done
based on presumptive phenotypic appearance of colonies
on the medium, and confirmed using insertion sequence
6110-based PCR method as previously described [23].
Isolates were tested for resistance to rifampicin, isoniazid
ethambutol and streptomycin using the L-J proportional
method, in concentrations of 40 μg/ml for rifampicin,
0.2 μg/ml for isoniazid, 2.0 μg/ml for ethambutol and
4.0 μg/ml for streptomycin, and all identified MDR-TB
isolates were tested for resistance to kanamycin and
ofloxacin in concentrations of 30 μg/ml and 2.0 μg/
ml, respectively, using the method as previously
described [24]. All samples resistant to rifampicin, a
random sample of 20 isolates from previously treated
patients susceptible to isoniazid and rifampicin, and a
random sample of isoniazid resistant isolates that
were susceptible to isoniazid were retested by the supra-
national reference laboratory in Borstel (Germany) for
external quality assurance.
Preparation of crude genomic DNA from Mycobacterium
tuberculosis for use as template in PCRs
A total of 1039 isolates were stored in replicates at the
(NTRL) at −80°C. To extract DNA, the selected isolates
Figure 1 Map of Uganda showing health facilities which participated in the study and the NTLP zones.
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temperature for 12 hours. The vials were centrifuged at
15,000 g for 30 min and the pellet was washed twice with
500 ul of Qiagen PCR water. The final pellet was re-
suspended in 100 μl of Qiagen PCR-water, heated at 95°C
for 30 minutes to kill and lyse the bacilli and later soni-
cated for 15 min at room temperature. The extracted
crude genomic DNA in the supernatant was recovered by
centrifugation at 15,000 g for 30 min; the latter was used
immediately in the real time PCR (RT-PCR) assay or
stored at −20°C for future use.
SNP typing of Mycobacterium tuberculosis
A SNP (Rv0040c-0619n) identifying the Uganda II (MTB)
with its accompanying designed primers and probes as
previously described [18] was used in a real-time PCR
[(RT)PCR] SNP assay. The (RT)PCR analysis involved 2
steps. The first was amplification (40 cycles of 95°C for
10 sec, 57°C for 10 sec and 72°C for 10 sec of the target re-
gion(s)) to generate amplicons for the melting curve ana-
lysis. The results of melting curves were analyzed using
LightCycler® software version 1.5 to assign an isolate to a
particular lineage depending on the melting temperature
at which the hybridization probes dissociates from theamplicons. In all the assays we used MTB Uganda (MTB
L4-U) genomic DNA from our laboratory, H37Rv gen-
omic DNA (MTB lineage 4) and Central Asian strain
(lineage 3) genomic DNA as control DNA.
HIV testing
HIV testing at all the 44 health care facilities followed the
national algorithm using Unigold® (Trinity Biotech,
Wiclock, Ireland) and Determine® (Abbot, Tokyo, Japan)
as the screening and confirmatory tests respectively. A
third kit, Stat-Pak® (Chethambutolio Medford NY, USA)
was used when a mismatch between the confirmatory and
the screening HIV test results on the same sample were
reported. All participants were offered this test algorithm
in accordance with the Uganda Ministry of Health
guidelines.
Data management and analysis
Data on demographics, microscopy, culture and DST re-
sults was double entered in epi-info V6 (2000 CDC At-
lanta GA USA), as part of the anti-TB drug resistance
study, while results on molecular studies was entered in
MS Excel. Analysis was done in Stata v10 (STATA Corp.
College Station TX USA.) The Chi-square or the 2-sided
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parison of categorical variables. Univariate and multivari-
ate analysis was done using logistic regression to identify
variables associated with the T2/Uganda II MTB genotype.
Contribution of the variables to the model was done using
the likelihood ratio Chi square test. All significance testing
was at the 95% confidence level.
Our primary outcome was the proportion of MTB pa-
tients with the Uganda II family calculated as a propor-
tion across all clusters after weighing for the exact
sampling probabilities for each new individual patient
for whom DST results were available. Associations with
MDR, HIV infection, patient age, previous history of TB
treatment and urban or rural residence were also stud-
ied. In all these calculations, confidence intervals and p-
values were adjusted for cluster design by first order
Taylor linearization and by second order correlation of
Rao and Scott of the Pearson X2 respectively as imple-
mented by Stata svy commands [25].
Ethical approval and consent procedure
Ethical and scientific approval of the study was granted
by Makerere University College of Health Sciences, Fac-
ulty of Medicine review board and the Uganda National
Council of Science and technology. All adult participants
gave written informed consent before participation. Add-
itionally, we obtained written informed consent from the
parent/guardian of participants under the age of 18 years.
The consent process included storage and use of the col-
lected sputum samples for further studies.
Results
Out of the 1537 patients included in the survey, 127
were culture negative, 77 samples were contaminated,
eight samples grew non-tuberculous mycobacteria, and
1325 samples grew MTB based on IS6110-PCR analysis.
Of these 1325 isolates, 324 did not grow on subculture
(done for molecular analysis), leaving 1001 available for
genotyping. Twenty-eight of these were excluded from
further analysis due to inconclusive genotyping results.
Thus, results on MTB genotype were available for single
isolates of 973 patients. Of these isolates, 630 (64.8%)
belonged to male participants. Mean age of participants
was 34.7 years, 25–34 years being the modal age group
(n = 330; 34.3%). Out of the eight zones that participated
in this study, south west zone contributed the highest
number of isolates (n = 313; 32.0%). Of the 973 patients,
297 (30.5%) tested positive for HIV, 217 (22.3%) of
whom had already tested HIV positive before enrolment.
Previously treated TB patients contributed 78 (8.1%) of
the isolates. Generally there was no difference with re-
gard to demographic characteristics (with exception of
the zone where the patient was enrolled) of the patients
included in the survey between those whose isolateswere included and those whose were not included in the
molecular typing (Table 1).
Of the 973 MTB isolates analysed with valid results, 422
(43.4%) were of the Uganda II family. Among the eight
NTLP zones that participated in this survey, south west zone
had the highest proportion of this genotype, 172/313 (55.0%;
95% CI, 49.2-60.5), while south east had the lowest 7/35
(19.4%; 95% CI 8.1-36.0). We found the Uganda II family
less distributed in the east and south east zones as compared
to the south west zone (p < 0.001) (Table 2). The 25–34 year
age group had the highest proportion of the Uganda II fam-
ily (48.2%) although there was no statistical significance of
the differences in distribution of this genotype among the
different age groups. We found no association between the
Uganda II family distribution with previous history of TB
treatment and rural/urban residence.
On multivariable analysis, isolates belonging to other ge-
notypes other than the Uganda II family were more likely
to have resistance to any of the first-line drugs (ORadj 2.9;
95% CI, 1.63-5.06; p = 0.001) and more likely to be MDR
(ORadj 4.9; 95% CI, 1.15-20.60; p = 0.032) than the Uganda
II family, even though MDR isolates were few (n = 23). In-
cluded in our model for adjustment were the NTLP zone
where the patient was enrolled, patient category (new or
previously treated), age group, and participant residence
(rural/urban) (Table 3). In NTLP zones where the Uganda
II family was less distributed, participants had an increased
risk of up almost twice (ORadj 1.8; 95% CI, 1.25-2.62; p =
0.001) of having drug resistance as compared to south west
zone where this genotype contributed a larger proportion
to the sample (Table 4). No association between HIV
infection and the Uganda II family (OR 1.09; 95% CI, 0.73-
1.63; p = 0.648) was established at univariable analysis.
Discussion
In this cross-sectional molecular analysis of M. tubercu-
losis strains circulating in Uganda, we clearly demon-
strate the Uganda II family as the major cause of
morbidity due to TB in the country although at different
levels of predominance in the eight NTLP (i.e. geo-
graphic) zones. Its frequency was highest in the south
west and lowest in the south east zone (see Figure 1).
Our study showed that this genotype is less likely to de-
velop resistance to any of the anti-TB drugs compared
to all the other genotypes taken as a single group, but
no association with HIV infection was demonstrated.
We found the Uganda II family about 2.9 times less
likely to be resistant to any of the first-line anti-TB drugs
and almost 5 times less likely to be MDR as compared to
the non Uganda II MTB family. It confirms our observa-
tion from a similar survey done in Kampala where the T2
Uganda genotype strains were less likely to be drug resist-
ant compared to other, geographically more diverse geno-
types such LAM, CAS and T1 [22]. That the Uganda II
Table 1 Characteristics of patients enrolled in the study
Characteristic Enrolled in survey
N = 1537 n (%)
Included for molecular
analysis N = 973 n (%)
Not included for molecular
analysis N = 564 n (%)
p-value
Sex Male 1018 (66.2) 630 (64.7) 388 (68.8) 0.106
Female 519 (33.8) 343 (35.3) 176 (31.2)
Age 13-14 33 (2.2) 21 (2.2) 12 (2.1) 0.956
15-24 299 (19.5) 189 (19.8) 108(19.2)
25-34 521 (33.4) 330 (34.3) 191 (34.0)
35-44 366 (23.8) 235 (24.5) 131 (23.3)
45-54 167 (10.9) 100 (10.4) 67 (11.9)
>55 139 (9.0) 86 (9.0) 53 (9.43)
HIV already diagnosed positive Yes 339 (22.1) 217 (22.3) 122 (21.6) 0.586
No 873 (53.6) 527 (54.2) 296 (52.5)
Unknown 375 (24.4) 229 (23.5) 146 (25.9)
TB control Zone South West 482 (31.4) 278 (28.6) 204 (36.2) 0.004
Kampala 457 (29.7) 313 (31.2) 144 (25.5)
South East 97 (6.3) 59 (6.1) 38 (6.7)
Eastern 53 (3.5) 28 (2.9) 25 (4.4)
North East 152 (9.9) 89 (9.2) 63 (11.2)
North 52 (3.4) 36 (3.7) 16 (2.8)
North West 149 (9.7) 104 (10.7) 45 (8.0)
Western 95 (6.2) 66 (6.8) 29 (5.1)
HIV results at (re)testing Positive 469 (30.5) 297 (30.5) 172 (30.5) 0.216
Negative 1054 (68.6) 664 (68.2) 390 (69.2)
Missing 14 (0.91) 12 (1.23) 2 (0.35)
Previous TB treatment Yes 140 (9.2) 78 (8.1) 62 (11.3) 0.057
No 1397 (90.8) 883 (91.9) 500 (89.0)
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supported by the higher levels M/DR-TB in zones where
this genotype is less prevalent such as the east zone. Here
the prevalence of drug resistance was up to almost 2 times
higher than in the south west zone where the majority of
the isolates belonged to the Uganda II family after adjust-
ing for patients’ HIV status, treatment category, rural or
urban residence and sex (Table 4). The negative associ-
ation reported in our earlier analysis [22] between the T2
Uganda genotype and any drug resistance is thus con-
firmed in this study, and also exists for MDR (stronger
than even the association with any resistance), possibly
due to larger numbers of MDR-TB patients to establish a
statistically significant difference.
Contrary to our findings, in some high burden TB set-
tings the predominant MTB genotype has been associ-
ated with M/DR. The Beijing genotype in particular has
been documented to cause outbreaks of MDR-TB where
this strain is the major cause of TB morbidity [26]. It re-
mains a subject for further analysis whether the Uganda
II family is inherently less likely to become drug-
resistant (i.e. has a lower potential for acquiring drugresistance), or that drug-resistant Uganda II family
strains are less easily transmitted than other drug-
resistant strains. The latter could occur if for example
(multi)drug-resistant Uganda II strains cause clinical in-
fections with lower bacterial load, or show higher cure
rates with first-line treatment, than do (multi)drug-re-
sistant strains of other genotypes. This could reflect dif-
ferences in adaptation to the Ugandan host population
between the more indigenous Uganda II family strains
and more recently imported strains such as LAM, CAS
and T1. In addition, one could speculate that predomin-
ance of the Uganda II family plays a causative role with
regard to reported low levels anti-TB drug resistance in
Uganda [5], and that similar genotypic differences in as-
sociation with drug resistance exist elsewhere in sub-
Saharan Africa where low levels of (M)DR-TB have been
reported.
Despite a high TB/HIV co-infection rate in our sample
(30.2%) we found no association between HIV infection
and Uganda II strains similar to findings of related stud-
ies elsewhere in SSA [27]. This finding suggests that the
predominance of the Uganda II strains is unlikely to be
Table 2 Analysis of risk factors associated with Uganda II family among sputum smear-positive TB patients in Uganda
Risk Factor Proportion n/N (%) N = 961 ** Univariate analysis
OR (95% CI) p-value
Sex Male 279/630 (44.3) 1.12 (0.83-1.52) 0.420
Female 143/343 (41.7) Ref.
Age 15-24 71/189 (37.6) Ref.
13-14 10/21 (47.6) 0.66 (0.25-1.72) 0.386
25-34 159/330 (48.2) 0.65 (0.45-9.20) 0.017
35-44 96/235 (40.9) 0.87 (0.62-1.21) 0.406
45-54 45/100 (45.0) 0.74 (0.46- 1.19) 0.210
>55 35/86 (40.7) 0.87 (0.47-1.60) 0.660
Zone South West 172/313 (55.0) Ref.
Kampala 112/278(40.3) 0.55 (0.36-0.83) 0.006
Eastern 22/89 (24.7) 0.26 (0.17-0.41) <0.001
South East 7/36 (19.40) 0.20 (0.14-0.28) <0.001
North East 26/59 (44.1) 0.64 (0.35-1.17) 0.146
North 10/28 (35.7) 0.45 (0.31-0.64) <0.001
North West 20/66 (30.3) 0.32 (0.18-0.55) <0.001
Western 53/104 (51.0) 0.86 (0.43-1.72) 0.667
Previously treated for TB Yes 31/78 (39.7) 0.85 (0.58-1.25) 0.403
HIV status Positive 130/442 (29.4) 1.09(0.73-1.63) 0.648
Diagnosis made in an urban setting Yes 267/585 (45.6) 0.80 (0.49-1.32) 0.385
** Odds ratios and confidence intervals adjusted for cluster design.
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lating MTB population as a result of the HIV epidemic.
Since we observed significant geographical variations
with respect to the distribution of the Uganda II family,
it can be speculated that the north east and south east
zones where this genotype is less distributed might have
a diversity of MTB strains that are imported through
cross-border movement with neighbouring countries
such as Kenya, Tanzania and beyond. Indeed the eastern
border of Uganda acts as the entry/exit (Busia and
Malaba) for goods and people from Mombasa port and
the northern part of Kenya and, the Kilimanjaro region
in Tanzania, while Kampala being the capital city is the
major business centre and a pathway for people entering
and exiting Uganda from all over the world. Human traf-




Proportion **OR 95% CI p-va
Uganda II 26/422 (6.2) Ref.
Other 91/549 (16.6) 2.9 1.63-5.06 0.001
Others included in the model were National TB/Leprosy Program (NTLP) zone, patie
residence (rural/urban).
** Odds ratios adjusted for cluster design.of communicable diseases, including TB, with higher
probability of strain diversity than in the south west
zone. The other possibility could be that the Uganda II
family might be genetically more adapted to indigenous
human populations of the south west than the east and
south east zones. Both hypotheses can only be confirmed
through further research.
Limitations
Our study had limitations. We did not fully characterise
the non-Uganda II family into specific lineages that have
been previously documented as significantly contributing
to the TB burden in this setting. Therefore we could not
fully conclude which particular strain drives drug resist-
ance in this locality and any associated factors such as
transmissibility and potential to develop drug resistancerug resistance among sputum smear-positive TB patients
MDR
lue Proportion **OR 95% CI p-value
3/422 (0.7) Ref.
19/530 (3.5) 4.9 1.15-20.60 0.032
nt category (new or previously treated), HIV status, age group, and
Table 4 Multivariable analysis of ‘any resistance’ and ‘NTLP zone’ in relation to the proportion of the Uganda II family
among the sputum-smear positive TB patients in Uganda
Total number of isolates N = 973 Proportion of T2 isolates n (%) Univariate analysis Multivariable analysis
Zone **OR (95% CI) p-value OR (95% CI) *p-value
South West 313 172 (55.0) Ref. Ref.
Kampala 278 112 (40.3) 1.9 (1.34-2.79) 0.004 1.8 (1.23-2.53) 0.005
Eastern 89 22 (23.6) 1.9 (0.76-4.79) 1.57 1.9 (0.8-4.43) 0.122
South East 36 7 (19.4) 1.7 (1.26-2.35) 0.001 1.8 (1.25-2.62) 0.003
North East 59 28 (44.1) 1.9 (1.27-2.73) 0.030 1.8 (1.23-2.53) 0.001
North 28 10 (35.7) 0.8 (0.58-1.08) 0.137 1.0 (0.69-1.45) 0.980
North West 66 20 (30.3) 0.5 (0.27-1.10) 0.295 0.73 (2.05-2.78) 0.113
Western 104 53 (51.0) 1.5 (0.22-1.61) 0.134 1.6 (0.89-2.78) 0.546
** Odds ratios confidence intervals and p-values adjusted for cluster design.
* = P value for the difference in resistance between the south western zone and each of the other zones included in the study.
Other variables included in the model are patient category, sex, residence (rural/urban), HIV status.
Ref = reference category.
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out the role of the predominant genotype in the ob-
served low levels of anti-TB drug resistance in this local-
ity and our earlier report [22], though limited in terms
of geographical coverage, fully characterised the less pre-
dominant MTB lineages in relation M/DR-TB and HIV
infection. We however strongly recommend a more in
depth analysis to characterize the ‘non- Uganda II family’
and its distribution throughout Uganda. Secondly, we
employed a typing method (identification of genotype-
specific SNPs) that was different from the method that
was used for the Kampala survey (spoligotyping) in
which the negative association of the T2 Uganda geno-
type with drug resistance was initially observed. How-
ever, earlier studies have shown that the T2 genotype
and the Uganda II genotype strongly overlap [18].
Thirdly, only sputum smear-positive TB patients were
included in the study since this was an extension of a
drug resistance survey. This sampling frame could limit
generalizability of our results to smear negatives should
there be a difference in the distribution of the Uganda II
family strains. Since differences in bacterial load and
resulting transmission fitness of drug resistant strains
may in part explain the observed association, it would be
interesting to extend the current study with sputum
smear-negative patients.
Few MDR patients were available to provide enough
power for analysis of associations between the Uganda II
family and MDR although we managed to demonstrate
this with wide confidence interval.
Conclusion
This study shows the Uganda II family to be the pre-
dominant MTB genotype in Uganda and confirms earlier
findings that this genotype is less likely to be drug resist-
ant compared to other genotypes combined. This may inpart explain the low levels of drug resistance found in
Uganda. Similar negative associations between the pre-
dominant indigenous MTB strains and drug resistance
may exist elsewhere in SSA [28].
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